Eton Pharmaceuticals, Inc. (ETON)
NASDAQ: ETON · Real-Time Price · USD
61.48
-1.95 (-3.07%)
Aug 19, 2026, 4:00 PM EDT - Market closed
Eton Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 26.85 | 25.94 | 14.94 | 21.39 | 16.31 | 14.41 |
Cash & Short-Term Investments | 26.85 | 25.94 | 14.94 | 21.39 | 16.31 | 14.41 |
Cash Growth | 5.78% | 73.69% | -30.17% | 31.17% | 13.18% | -32.35% |
Receivables | 24.89 | 11.76 | 5.36 | 3.41 | 1.85 | 5.47 |
Inventory | 10.14 | 15.42 | 15.23 | 0.91 | 0.56 | 0.55 |
Prepaid Expenses | 6.73 | 7.46 | 5.49 | 1.13 | 1.29 | 3.18 |
Total Current Assets | 68.6 | 60.58 | 41.02 | 26.84 | 20 | 23.6 |
Property, Plant & Equipment | 1.47 | 0.64 | 0.21 | 0.15 | 0.26 | 0.22 |
Other Intangible Assets | 45.68 | 30.88 | 34.88 | 4.74 | 4.75 | 3.62 |
Other Long-Term Assets | 0.06 | 0.02 | 0.01 | 0.01 | 0.01 | 0.02 |
Total Assets | 115.81 | 92.11 | 76.12 | 31.74 | 25.03 | 27.47 |
Accounts Payable | 14.41 | 10.98 | 4.17 | 1.85 | 1.77 | 1.77 |
Accrued Expenses | 18.95 | 15.94 | 15.7 | 8.96 | 3.66 | 1.37 |
Current Portion of Long-Term Debt | 8.83 | 8.79 | - | 5.38 | 1.03 | 1.42 |
Current Portion of Leases | 0.24 | 0.07 | 0.08 | 0.05 | - | - |
Current Unearned Revenue | 0.33 | 0.46 | - | - | - | - |
Other Current Liabilities | 2.38 | 2.26 | - | - | - | - |
Total Current Liabilities | 45.12 | 38.49 | 19.95 | 16.24 | 6.46 | 4.56 |
Long-Term Debt | 19.08 | 21.77 | 29.81 | - | 5.38 | 5.26 |
Long-Term Leases | 1.08 | 0.46 | 0.11 | 0.02 | 0.11 | 0.02 |
Long-Term Unearned Revenue | 1.62 | 1.76 | - | - | - | - |
Other Long-Term Liabilities | 2.32 | 3.48 | 1.83 | - | - | - |
Total Liabilities | 69.22 | 65.96 | 51.7 | 16.26 | 11.95 | 9.84 |
Common Stock | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 |
Additional Paid-In Capital | 145.92 | 138.62 | 132.29 | 119.52 | 116.19 | 111.72 |
Retained Earnings | -99.36 | -112.49 | -107.89 | -104.07 | -103.13 | -94.11 |
Total Common Equity | 46.59 | 26.15 | 24.43 | 15.48 | 13.08 | 17.63 |
Shareholders' Equity | 46.59 | 26.15 | 24.43 | 15.48 | 13.08 | 17.63 |
Total Liabilities & Equity | 115.81 | 92.11 | 76.12 | 31.74 | 25.03 | 27.47 |
Total Debt | 29.23 | 31.08 | 29.99 | 5.46 | 6.52 | 6.7 |
Net Cash (Debt) | -2.38 | -5.14 | -15.06 | 15.93 | 9.78 | 7.71 |
Net Cash Growth | - | - | - | 62.90% | 26.85% | -45.52% |
Net Cash Per Share | -0.08 | -0.19 | -0.58 | 0.62 | 0.39 | 0.31 |
Filing Date Shares Outstanding | 28.58 | 27.28 | 26.82 | 25.69 | 25.46 | 24.63 |
Total Common Shares Outstanding | 28.29 | 27.05 | 26.71 | 25.69 | 25.35 | 24.63 |
Working Capital | 23.48 | 22.09 | 21.07 | 10.6 | 13.54 | 19.05 |
Book Value Per Share | 1.65 | 0.97 | 0.91 | 0.60 | 0.52 | 0.72 |
Tangible Book Value | 0.91 | -4.72 | -10.45 | 10.74 | 8.32 | 14.01 |
Tangible Book Value Per Share | 0.03 | -0.17 | -0.39 | 0.42 | 0.33 | 0.57 |
Machinery | 0.24 | 0.52 | 0.38 | 0.35 | 0.34 | 0.4 |
Construction In Progress | - | - | - | - | 0.01 | - |
Leasehold Improvements | 0.23 | 0.3 | 0.1 | 0.1 | 0.07 | 0.07 |